L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma
Modern Pathology · 2024-05 · 37 (5) · 100467
DOI: 10.1016/j.modpat.2024.100467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2024-05. Verfasst von Mohammed Alghamdi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory M…. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Biomarkers, Tumor, Neural Cell Adhesion Molecule L1. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cycle for Survival, National Institutes of Health.
Abstract (Originalsprache)
Renal low-grade oncocytic tumor (LOT) is a recently recognized renal cell neoplasm designated within the "other oncocytic tumors" category in the 2022 World Health Organization classification system. Although the clinicopathologic, immunohistochemical, and molecular features reported for LOT have been largely consistent, the data are relatively limited. The morphologic overlap between LOT and other low-grade oncocytic neoplasms, particularly eosinophilic chromophobe renal cell carcinoma (E-chRCC), remains a controversial area in renal tumor classification. To address this uncertainty, we characterized and compared large cohorts of LOT (n = 67) and E-chRCC (n = 69) and revealed notable differences between the 2 entities. Clinically, LOT predominantly affected women, whereas E-chRCC showed a male predilection. Histologically, although almost all LOTs were dominated by a small-nested pattern, E-chRCC mainly showed solid and tubular architectures. Molecular analysis revealed that 87% of LOT cases harbored mutations in the tuberous sclerosis complex (TSC)-mTOR complex 1 (mTORC1) pathway, most frequently in MTOR and RHEB genes; a subset of LOT cases had chromosomal 7 and 19q gains. In contrast, E-chRCC lacked mTORC1 mutations, and 60% of cases displayed chromosomal losses characteristic of chRCC. We also explored the cell of origin for LOT and identified L1 cell adhesion molecule (L1CAM), a collecting duct and connecting tubule principal cell marker, as a highly sensitive and specific ancillary test for differentiating LOT from E-chRCC. This distinctive L1CAM immunohistochemical labeling suggests the principal cells as the cell of origin for LOT, unlike the intercalated cell origin of E-chRCC and oncocytoma. The ultrastructural analysis of LOT showed normal-appearing mitochondria and intracytoplasmic lumina with microvilli, different from what has been described for chRCC. Our study further supports LOT as a unique entity with a benign clinical course. Based on the likely cell of origin and its clinicopathologic characteristics, we propose that changing the nomenclature of LOT to "Oncocytic Principal Cell Adenoma of the Kidney" may be a better way to define and describe this entity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, University of Pen…
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: cheny@mskcc.org.
Förderung
- NCI NIH HHS
- Cycle for Survival
- National Institutes of Health
- University of Pennsylvania
- National Cancer Institute
Zitieren
APA
Alghamdi, M., Chen, J. F., Jungbluth, A., Koutzaki, S., Palmer, M. B., Al-Ahmadie, H. A., Fine, S. W., Gopalan, A., Sarungbam, J., Sirintrapun, S. J., Tickoo, S. K., Reuter, V. E., & Chen, Y. B. (2024). L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma. Modern Pathology, 37(5), 100467. https://doi.org/10.1016/j.modpat.2024.100467
Vancouver
Alghamdi M, Chen JF, Jungbluth A, Koutzaki S, Palmer MB, Al-Ahmadie HA, et al. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma. Modern Pathology. 2024;37(5):100467. doi:10.1016/j.modpat.2024.100467
BibTeX
@article{Alghamdi2024,
author = {Alghamdi, Mohammed and Chen, Jie-Fu and Jungbluth, Achim and Koutzaki, Sirma and Palmer, Matthew B and Al-Ahmadie, Hikmat A and Fine, Samson W and Gopalan, Anuradha and Sarungbam, Judy and Sirintrapun, S Joseph and Tickoo, Satish K and Reuter, Victor E and Chen, Ying-Bei},
title = {L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma},
journal = {Modern Pathology},
year = {2024},
volume = {37},
number = {5},
pages = {100467},
doi = {10.1016/j.modpat.2024.100467}
}
EUVIMED